The ELAVL2 antibody targets the ELAVL2 protein, a member of the Embryonic Lethal Abnormal Vision-like (ELAVL/Hu) family of RNA-binding proteins. ELAVL2. also known as HuB, plays a critical role in post-transcriptional gene regulation by stabilizing mRNA and enhancing translation, particularly in neuronal and germline tissues. It is involved in neurodevelopment, synaptic plasticity, and maintaining neuronal function. Dysregulation of ELAVL2 has been linked to neurological disorders, cancers, and neurodegenerative diseases.
ELAVL2 antibodies are widely used in research to study its expression, localization, and interactions in cellular and tissue contexts. These antibodies enable detection via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Commercial ELAVL2 antibodies are typically raised in rabbits or mice, with validation in specific experimental models.
Research applications include investigating ELAVL2's role in mRNA stability during neural differentiation, its overexpression in glioblastoma, and its potential as a biomarker. Cross-reactivity with other ELAVL family members (e.g., HuR, HuC, HuD) is a key consideration, requiring validation via knockout controls or epitope-specific designs.
Overall, ELAVL2 antibodies are essential tools for exploring RNA-protein dynamics in health and disease, particularly in neuroscience and oncology.